Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Closing the gap: Genetic profiling of B-cell lymphomas using integrative whole-exome and whole-transcriptome sequencing

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAditya SharmaPKPrabhjot Kaur

Discussion

Loading...

Member takes

Overview

Results demonstrate high identification of pathogenic variants in B-cell lymphomas, suggesting integrative genetic profiling enhances clinical outcomes.

Key Points

  • To investigate the use of whole-exome and whole-transcriptome sequencing for B-cell lymphomas to identify clinically relevant variants.
  • Established a biobank for B-cell lymphoma specimens.
  • Utilized whole-exome and whole-transcriptome sequencing for genomic and transcriptional data integration.
  • Identified genetic variants through next-generation sequencing and bioinformatics analysis.
  • 79% of analyzed specimens showed clinically relevant variants, with a total of 56 pathogenic variants identified.
  • All diffuse large B-cell lymphoma cases had at least one pathogenic variant, particularly TP53.
  • Identified complex genetic alterations such as translocations and loss of heterozygosity affecting key genes.

Cite This Study

Sharma et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d56ehttps://doi.org/10.1182/blood-2025-7067
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeted panel sequencing for refining B-cell lymphoma diagnosis: a real-life, reference center experience2026 · 2 citations
  2. 2Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma2026
  3. 3A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing2025
  4. 4Abstract PO-016: Test-the-test: Clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for lymphoma patients2024
  5. 5Real-world patient-based next-generation sequencing assessments identify a high-risk subgroup and associated gene signature in diffuse large B cell lymphoma2025